Cancer　vaccines　targeting　tumor　specific　neoantigens　derived　from　nonsynonymous　mutations　of　tumor　cells　have　emerged　as　an　effective　approach　to　induce　antitumor　T　cells　responses　for　personalized　cancer　immunotherapy.　Despite　the　enormous　potential　of　synthetic　peptides　as　a　common　modality　for　neoantigen　vaccines,　their　practical　efficacy　was　limited　due　to　their　relatively　low　immunogenicity.　Herein,　we　modify　neoantigen　peptide　(Adpgk)　derived　from　MC-38　colon　carcinoma　by　supplementing　ten　consecutive　positively-charged　lysines　(10　K-Adpgk)　to　obtain　cationic　polypeptide.　And　then　we　made　them　self-assemble　with　toll-like　receptor　9　(TLR-9)　agonist　CpG　oligodeoxynucleotides　(CpG　ODN)　adjuvant　directly　forming　antigen/adjuvant　integrated　nanocomplexes　(PCNPs)　through　electrostatic　interaction　for　potent　tumor　immunotherapy.　The　optimal　formed　PCNPs　were　around　175　nm　with　uniform　size　distribution　and　could　maintain　stability　in　physiological　saline　solution.　CpG　ODN　and　10　K-Adpgk　in　the　formed　PCNPs　could　be　effectively　uptake　by　dendritic　cells　(DCs)　and　stimulate　the　maturation　of　DCs　as　well　as　improving　the　efficiency　of　antigen　crosspresentation　efficiency　in　vitro.　Furthermore,　the　PCNPs　vaccine　could　markedly　improve　neoantigen　and　adjuvant　co-delivery　efficiency　to　lymphoid　organs　and　activate　cytotoxic　T　cells.　In　addition,　vaccination　with　PCNPs　could　not　only　offer　prophylactic　to　protect　mice　from　challenged　MC-38　colorectal　tumors,　but　also　achieve　a　better　anti-tumor　effect　in　an　established　colorectal　tumor　model,　and　significantly　prolong　the　survival　rate　of　tumor-bearing　mice.　Therefore,　this　work　provided　a　versatile　but　effective　method　for　neoantigen　peptide　and　CpG　ODN　co-assembly　vaccine　platform　for　efficient　colorectal　cancer　immunotherapy.